Celularity Inc. GXGXW
Set alert
At close
- Open
- 1.17
- Prev close
- 1.70
- Mkt cap
- 237.67M
- Vol
- 2.61M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.17
- High
- 2.40
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Celularity Inc.
Celularity Inc., a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- celularity.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on GXGXW — it syncs with the Stock Master app.